Motilal Oswal sees 23% revenue CAGR for Molbio in FY26-29
In short
Motilal Oswal said Molbio could grow revenue by 23% a year from FY26 to FY29. It pointed to more use of the Truenat platform, a bigger assay menu, and growth in digital pathology and imaging.
This matters because the broker sees further upside in a stock that has already doubled from its IPO price. The report does not give the current price, target price, or exact recommendation.
What the reporting says
Motilal Oswal said Molbio’s revenue could grow at a 23% CAGR over FY26-29, driven by higher utilisation of its Truenat platform, expansion of its assay menu and growth in digital pathology and imaging, according to CNBC TV18’s summary. The source also says the stock is already doubled from its IPO price and that the bull case sees 70% upside. It is not stated whether this was a formal recommendation, nor are the current share price and target disclosed.
Why it matters
Motilal Oswal’s bull case for Molbio includes a 23% revenue CAGR over FY26-29, supported by higher utilisation of the Truenat platform, expansion of the assay menu, and growth in digital pathology and imaging businesses. The publisher summary says the stock has already doubled from its IPO price and that the bull case implies 70% upside. The source does not provide the current valuation, target price or whether this is an official company view.